Physician profile
Christopher Joncas
NPI 1336136456
$83,099.59
in general payments reported to CMS, 2019-2025
25 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $180 · 2023: $23K · 2024: $34K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $21K · Travel and Lodging: $5,769 · Food and Beverage: $4,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,571.00 |
| Consulting Fee | $20,625.00 |
| Travel and Lodging | $5,769.24 |
| Food and Beverage | $4,516.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $82,033.63 | 2023-2025 | Ingrezza |
| Pfizer INC. | $251.31 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $106.13 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sunovion Pharmaceuticals INC. | $79.42 | 2019 | |
| Novo Nordisk INC | $78.67 | 2020-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $51.93 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $45.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.38 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $40.00 | 2024-2025 | Rexulti |
| Lundbeck LLC | $39.02 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.47 | 2023-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $32.92 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $32.69 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $21.86 | 2019 | |
| Glaxosmithkline, LLC. | $21.72 | 2025 | Shingrix, Arexvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.55 | 2019 | |
| Seqirus USA INC | $20.98 | 2024 | Flucelvax, Fluad |
| Medtronic Vascular, INC. | $20.85 | 2020 | |
| Melinta Therapeutics, LLC | $19.57 | 2019 | |
| Mdd US Operations, LLC | $19.10 | 2020 | |
| Sanofi Pasteur INC. | $18.96 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2019 | |
| Inspire Medical Systems, INC. | $16.92 | 2025 | Inspire |
| Amarin Pharma, INC. | $14.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Joncas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.